Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 90, Issue 4, 2014, Pages 850-857

  Sheu, Tommy ^a,b   Heymach, John V ^b   Swisher, Stephen G ^b   Rao, Ganesh ^b   Weinberg, Jeffrey S ^b   Mehran, Reza ^b   McAleer, Mary Frances ^b   Liao, Zhongxing ^b   Aloia, Thomas A ^b   Gomez, Daniel R ^b  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL ORGANS; CHEMOTHERAPY; DISEASES; HAZARDS; RADIOTHERAPY;

CONCURRENT CHEMORADIATION; CONFIDENCE INTERVAL; DISEASE PROGRESSION; METHODS AND MATERIALS; NON SMALL CELL LUNG CANCER; PROGRESSION FREE SURVIVAL; PROPENSITY SCORE MATCHING; PROPORTIONAL HAZARDS;

DISEASE CONTROL;

CARBOPLATIN; CISPLATIN; ERLOTINIB; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LOCAL THERAPY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; AGE; ANALYSIS OF VARIANCE; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; LUNG RESECTION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; RADIATION DOSE FRACTIONATION; RADIOSURGERY; SECONDARY; SEX DIFFERENCE; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PNEUMONECTOMY; PROPENSITY SCORE; RADIOSURGERY; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 84908181105     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.07.012     Document Type: Article

References (30)

1. K.S. Albain, J.J. Crowley, and M. LeBlanc Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience J Clin Oncol 9 1991 1618 1626
2. R.R. Weichselbaum, and S. Hellman Oligometastases revisited Nat Rev Clin Oncol 8 2011 378 382
3. S. Hellman, and R.R. Weichselbaum Oligometastases J Clin Oncol 13 1995 8 10
4. A.J. Khan, P.S. Mehta, and T.W. Zusag Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC) Radiother Oncol 81 2006 163 167
5. J.L. Lopez Guerra, D. Gomez, and Y. Zhuang Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis Int J Radiat Oncol Biol Phys 84 2012 e61 e67
6. D. De Ruysscher, R. Wanders, and A. van Baardwijk Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: Long-term results of a prospective phase II trial (NCT01282450) J Thorac Oncol 7 2012 1547 1555
7. M.T. Congedo, A. Cesario, and F. Lococo Surgery for oligometastatic non-small cell lung cancer: Long-term results from a single center experience J Thorac Cardiovasc Surg 144 2012 444 452
8. P. Cheruvu, S.K. Metcalfe, and J. Metcalfe Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer Radiat Oncol 6 2011 80
9. A.B. Ashworth, S. Senan, and D.A. Palma An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer Clin Lung Cancer 2014 May 15 [Epub ahead of print]. http://dx.doi.org/10.1016/j.cllc.2014.04.003
10. M.D. Hasselle, D.J. Haraf, and K.E. Rusthoven Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer J Thorac Oncol 7 2012 376 381
11. N. Girard, V. Cottin, and F. Tronc Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases Lung Cancer 53 2006 51 58
12. M. Wronski, E. Arbit, and M. Burt Survival after surgical treatment of brain metastases from lung cancer: A follow-up study of 231 patients treated between 1976 and 1991 J Neurosurg 83 1995 605 616
13. S.B. Edge American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Handbook: From The AJCC Cancer Staging Manual 7th ed. 2010 Springer New York
14. J.M. Abrahams, M. Torchia, and M. Putt Risk factors affecting survival after brain metastases from non-small cell lung carcinoma: A follow-up study of 70 patients J Neurosurg 95 2001 595 600
15. A.V. Louie, G. Rodrigues, and B. Yaremko Management and prognosis in synchronous solitary resected brain metastasis from non-small-cell lung cancer Clin Lung Cancer 10 2009 174 179
16. M. Schemper, and T.L. Smith A note on quantifying follow-up in studies of failure time Control Clin Trials 17 1996 343 346
17. Leuven E, Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. 2003. Available at: http://fmwww.bc.edu/repec/bocode/p/psmatch2.ado. Accessed October 20, 2013.
18. P.C. Austin Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples Stat Med 28 2009 3083 3107
19. A. Ashworth, G. Rodrigues, and G. Boldt Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature Lung Cancer 82 2013 197 203
20. G.H. Griffioen, D. Toguri, and M. Dahele Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): Patient outcomes and prognostic factors Lung Cancer 82 2013 95 102
21. H.R. Withers, and S.P. Lee Modeling growth kinetics and statistical distribution of oligometastases Semin Radiat Oncol 16 2006 111 119
22. A.J. Weickhardt, B. Scheier, and J.M. Burke Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer J Thorac Oncol 7 2012 1807 1814
23. R.J. Downey, K.K. Ng, and M.G. Kris A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis Lung Cancer 38 2002 193 197
24. S. Collaud, R. Stahel, and I. Inci Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage Lung Cancer 78 2012 234 238
25. T. de Vin, B. Engels, and T. Gevaert Stereotactic radiotherapy for oligometastatic cancer: A prognostic model for survival Ann Oncol 25 2014 467 471
26. T.W. Flannery, M. Suntharalingam, and W.F. Regine Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery Int J Radiat Oncol Biol Phys 72 2008 19 23
27. A. Iwasaki, T. Shirakusa, and Y. Yoshinaga Evaluation of the treatment of non-small cell lung cancer with brain metastasis and the role of risk score as a survival predictor Eur J Cardiothorac Surg 26 2004 488 493
28. P. Bonnette, P. Puyo, and C. Gabriel Surgical management of non-small cell lung cancer with synchronous brain metastases Chest 119 2001 1469 1475
29. ClinicalTrials.gov. Phase II study of stereotactic body radiation therapy (SBRT) after first-line chemotherapy for metastatic NSCLC. ClinicalTrials.gov ID: NCT01185639. Available at: http://clinicaltrials.gov/show/NCT01185639. Accessed March 30, 2014.
30. A randomized phase II study assessing the efficacy of local consolidative therapy for non-small cell lung cancer patients with oligometastatic disease. ClinicalTrials.gov ID: NCT01725165. Available at: http://clinicaltrials.gov/show/clinicaltrials.gov/show/NCT01725165. Accessed March 30, 2014.